#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dent's disease Short-bowel syndrome Optic ischaemic neuropathy Pseudomyxoma peritonei Anti-glomerular basement membrane disease Depression Crohn's disease Raynaud's phenomenon Neoplasm malignant Synovial sarcoma metastatic Epstein-Barr virus infection Myelodysplastic syndrome with excess blasts Niemann-Pick disease Wolfram syndrome Thrombocytosis More trials…

    Learn about Rare Diseases

    Kearns-Sayre syndrome – Treatment Haemophilia A without inhibitors – Trials in Disease Adrenogenital syndrome – Life with Disease Advanced systemic mastocytosis – Treatment Mucopolysaccharidosis II – Basic Information Synovial sarcoma recurrent – Basic Information Hepatic angiosarcoma – Trials in Disease Synovial sarcoma recurrent – Life with Disease Bronchiolitis obliterans syndrome – Treatment Phenylketonuria – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vibegron Sym024 L-Histidine Hydrochloride Pd01B Alirocumab Barium Sulfate Bi 706321 Glatiramer Acetate Amlitelimab H2-Receptor Antagonist Pentoxifylline Argipressin Metformin Hydrochloride Dimeticone HALOBETASOL PROPIONATE Isis 696844 Tozinameran Ly3537982 Chloroprocaine Hydrochloride Zalunfiban More therapies…

    Learn about Your Condition

    Death neonatal Non-obstructive cardiomyopathy Laparoscopic surgery Peripheral spondyloarthritis Hyperglycaemia Basal cell naevus syndrome Petit mal epilepsy Retinitis pigmentosa Synovial sarcoma recurrent Thalassaemia beta Prolymphocytic leukaemia Pancreatic neoplasm Obliterative bronchiolitis Primary myelofibrosis Epidermolysis bullosa More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliera Regionale San Carlo

Azienda Ospedaliera Regionale San Carlo

Via Potito Petrone, Potenza, 85100, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Cetuximab
    Italy

  • Study on the Use of Landiolol Hydrochloride and Sodium Chloride for Patients Undergoing Mitral Valve Surgery to Prevent Low-Cardiac Output Syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • Landiolol Hydrochloride
    • Sodium Chloride
    Italy

  • Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    Italy Spain

  • Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Panitumumab
    Italy

  • Study of Valproic Acid, Capecitabine, and Radiotherapy for Patients with Low-Moderate Risk Rectal Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Valproate Semisodium
    • Capecitabine
    Italy

  • Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Gastric cancer
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Calcium Folinate
    • Capecitabine
    Italy

  • A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • SILYMARIN
    • Ribociclib
    Italy

  • Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

    Not yet recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Acute respiratory distress syndrome
    Investigated Drugs:
    • Pirfenidone
    • Sodium Chloride
    Italy

  • Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer stage II
    • Colon cancer stage III
    Investigated Drugs:
    • Capecitabine
    • Irinotecan
    • Oxaliplatin
    Italy
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!